Novacyt: Strong First-half Revenues Completes €3.5m in Bond Refinancing and Launches a €1.7m private placement

Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, is pleased to report strong first-half sales performance across the Group, the completion of €3.5m in bond refinancing and the launch of a €1.7m private placement of new shares to support the planned growth in the second half of 2015 and into 2016.

Visit Page

Novacyt completes €2m private placement to support second half sales growth

Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, reported earlier its strong first-half sales performance across the Group and the completion of €3.5m in bond refinancing. Today, Novacyt is pleased to announce a further private placement financing of €2m. Download press release

Visit Page

Novacyt strengthens board

Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics is pleased to announce the addition of new members to its Board as the Company prepares for the next stages of growth. Download press release

Visit Page